Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-4FN PET Imaging for Inflammation in ICI-Treated Tumors
NCT05335811Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2022
- Primary completion
- Aug 2028
- Modality
- CA (Contrast Agent), PET (Positron Emission Tomography)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 4-[18F]fluoro-1-naphthol in inflammation, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Preliminary efficacy signals from PET images correlating with clinical foci of ICI-related irAE at 1 year. Started Oct 2022; status: recruiting.
02
Drugs
4-[18F]fluoro-1-naphthol
03
Conditions
inflammation
Beyond the preview
Go deeper on NCT05335811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335811.